Literature DB >> 1710548

Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus.

M Ohlin1, V A Sundqvist, G Gilljam, U Rudén, F O Gombert, B Wahren, C A Borrebaeck.   

Abstract

Human monoclonal antibodies specific for human cytomegalovirus (CMV) antigens have been established using peripheral blood lymphocytes from a seropositive donor. Immortalization of antigen-specific B cells was achieved by Epstein-Barr virus transformation followed by somatic cell fusion of antigen-specific lymphoblastoid cells. Four clones producing high-affinity antibodies (0.2-7 x 10(9) M-1) specific for the viral matrix protein pp65 have been further characterized with respect to epitope specificity of secreted antibodies. The studied antigen represents a major protein produced by in vitro-cultivated virus, and is important in the serodiagnosis of CMV infection. The human monoclonal antibodies recognized different epitopes, some of which proved to be overlapping. The fine specificity of these antibodies was evaluated using synthetic peptides covering the sequence of pp65. The antibody MO58 recognized a linear epitope (residues 283-288) whereas antibody MO53 recognized a discontinuous epitope involving residues 208-216 and 280-285. Despite the close proximity of these epitopes, the antibodies did not compete with each other for the same binding site on intact antigen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1710548      PMCID: PMC1535436     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  35 in total

Review 1.  Strategy for the production of human monoclonal antibodies using in vitro activated B cells.

Authors:  C A Borrebaeck
Journal:  J Immunol Methods       Date:  1989-10-24       Impact factor: 2.303

2.  Genomic location of a human cytomegalovirus protein with protein kinase activity (PK68).

Authors:  T Somogyi; S Michelson; M J Masse
Journal:  Virology       Date:  1990-01       Impact factor: 3.616

3.  The effect of leucyl-leucine methyl ester on proliferation and Ig secretion of EBV-transformed human B lymphocytes.

Authors:  M Ohlin; L Danielsson; R Carlsson; C A Borrebaeck
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

4.  Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus.

Authors:  U Utz; W Britt; L Vugler; M Mach
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.

Authors:  H M Geysen; R H Meloen; S J Barteling
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

6.  Production and characterization of monoclonal antibodies specific for a glycosylated polypeptide of human cytomegalovirus.

Authors:  K S Kim; V J Sapienza; C M Chen; K Wisniewski
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

7.  Inhibition of cytomegalovirus late antigens by phosphonoformate.

Authors:  B Wahren; B Oberg
Journal:  Intervirology       Date:  1980       Impact factor: 1.763

8.  Regulation of cellular function by products of lysosomal enzyme activity: elimination of human natural killer cells by a dipeptide methyl ester generated from L-leucine methyl ester by monocytes or polymorphonuclear leukocytes.

Authors:  D L Thiele; P E Lipsky
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

9.  Murine monoclonal antibody to a single protein neutralizes the infectivity of human cytomegalovirus.

Authors:  L E Rasmussen; R M Nelson; D C Kelsall; T C Merigan
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

10.  Polymorphism of human cytomegalovirus glycoproteins characterized by monoclonal antibodies.

Authors:  L Pereira; M Hoffman; M Tatsuno; D Dondero
Journal:  Virology       Date:  1984-11       Impact factor: 3.616

View more
  7 in total

1.  IgM-enriched human intravenous immunoglobulin suppresses T lymphocyte functions in vitro and delays the activation of T lymphocytes in hu-SCID mice.

Authors:  T Vassilev; N Mihaylova; E Voynova; M Nikolova; M Kazatchkine; S Kaveri
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques.

Authors:  M Ohlin; M Silvestri; V A Sundqvist; C A Borrebaeck
Journal:  Clin Diagn Lab Immunol       Date:  1997-01

3.  Nuclear targeting of the tegument protein pp65 (UL83) of human cytomegalovirus: an unusual bipartite nuclear localization signal functions with other portions of the protein to mediate its efficient nuclear transport.

Authors:  S Schmolke; P Drescher; G Jahn; B Plachter
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

4.  Human antibody reactivity against the lower matrix protein (pp65) produced by cytomegalovirus.

Authors:  M Ohlin; B Plachter; V A Sundqvist; P G Steenbakkers; J M Middeldorp; C A Borrebaeck
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

5.  Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients.

Authors:  J Fagerberg; M Steinitz; H Wigzell; P Askelöf; H Mellstedt
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

6.  Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies.

Authors:  M Ohlin; V A Sundqvist; M Mach; B Wahren; C A Borrebaeck
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

7.  Development of a human antibody fragment directed against the alpha folate receptor as a promising molecule for targeted application.

Authors:  Nattihda Parakasikron; Chatchai Chaotham; Pithi Chanvorachote; Chanida Vinayanuwattikun; Visarut Buranasudja; Pornchanok Taweecheep; Kannika Khantasup
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.